Semaglutide may affect the absorption of orally administered medications via delayed gastric emptying. Review all current medications with the prescriber.
Semaglutide's primary mechanism for drug-drug interactions is delayed gastric emptying, which can alter the absorption of orally administered medications. Effects are most pronounced during titration and dose escalation when gastric motility changes are largest. The FDA prescribing information and post-marketing surveillance provide a useful framework, but clinicians should review each patient's complete medication list at initiation.
Semaglutide may reduce the efficacy of oral hormonal contraceptives by delaying their absorption. The FDA prescribing information recommends that patients using oral contraceptives switch to a non-oral contraceptive method or add a barrier method for 4 weeks after starting semaglutide and for 4 weeks after each dose escalation. Non-oral options include intrauterine devices, contraceptive implants, contraceptive injections, transdermal patches, and vaginal rings. This is one of the most clinically important interactions and is sometimes overlooked in telehealth-based prescribing.
When semaglutide is added to insulin or to sulfonylureas (such as glipizide, glyburide, glimepiride), hypoglycemia risk increases. The standard approach is to reduce the dose of insulin or sulfonylurea at semaglutide initiation, often by 20–25%, and to monitor blood glucose closely during titration. Patients should be educated about hypoglycemia symptoms and have appropriate response strategies.
Delayed gastric emptying can alter the absorption profile of oral medications with narrow therapeutic windows. Examples include warfarin (monitor INR), levothyroxine (monitor TSH), anti-seizure medications (monitor levels where available), and immunosuppressants such as cyclosporine and tacrolimus (monitor levels). The clinical relevance varies by medication and patient; many oral drugs are not meaningfully affected.
Semaglutide delays acetaminophen absorption, reducing peak concentration and delaying time to peak. Total exposure (AUC) is generally similar. This is rarely clinically meaningful but may be relevant for time-dependent analgesic effects.
There is no specific contraindication to alcohol with semaglutide, but combined effects on the gastrointestinal system can amplify nausea, gastritis, and dehydration. Patients with type 2 diabetes on insulin or sulfonylureas should be additionally cautious about alcohol-induced hypoglycemia.
Semaglutide is not metabolized by cytochrome P450 enzymes — it is degraded by proteolytic cleavage of its peptide backbone. Semaglutide does not induce or significantly inhibit major CYP isoforms. Therefore, CYP-mediated drug-drug interactions are not expected, distinguishing it from many small-molecule drugs.
Semaglutide should not be used concurrently with other GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide). Combined GLP-1 activation lacks evidence of additional benefit and would predictably increase adverse events. Transitioning between GLP-1 agonists is appropriate; combined use is not.
Not necessarily — metformin is typically continued. Insulin and sulfonylurea doses are commonly reduced at semaglutide initiation to manage hypoglycemia risk. DPP-4 inhibitors are generally discontinued because they overlap mechanistically with semaglutide. SGLT-2 inhibitors are often continued and may complement semaglutide.
Semaglutide may reduce oral contraceptive effectiveness, particularly during titration. Use a non-oral contraceptive method or add a barrier method for 4 weeks after starting and after each dose escalation. Discuss specific contraceptive planning with your prescriber.
Semaglutide does not directly interact with most blood pressure medications. However, weight loss and reduced food intake can lower blood pressure, which may require dose adjustment of antihypertensives — particularly diuretics — during therapy.
Compounded semaglutide · MD/DO oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000
Citations supporting clinical and regulatory statements on this page. External links open in a new tab.
Verification methodology: /how-we-verify.html · Editorial accuracy: medically reviewed by Michael Baghdassarian, M.D. · Last reviewed 2026-06-01.